Oppenheimer Maintains a 'Perform' on Teva Pharma (TEVA); Wait for Clarity on Pipeline
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.77 +0.68%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer maintains a 'Perform' on Teva Pharma (NASDAQ: TEVA).
Analyst, Christopher Holterhoff, said, "TEVA reported 2Q12 adj. EPS of $1.28, slightly above our $1.27 est., on rev. of $~5B, vs. our est. of ~$5.1B. We note that TEVA launched 12 products during the quarter, representing $17B in brand value. TEVA purchased ~3.5M shares ($35M aggregate spend) during 2Q12 ($667M aggregate spend on $3B repurchase program in 1H12). We highlight that TEVA also paid down ~$500M in debt and refinanced $3.4B of short-term debt which improved debt-to-EBITDA ratio to 2.2x from 2.6x. We adjust our estimates and look for insight from management into long-term strategic initiatives, pipeline developments, and BD commentary at the 12/11 Analyst Day."
FY12 EPS Estimate raised from $5.38 to $5.40 and FY13 from $5.91 to $6.01.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Analyst, Christopher Holterhoff, said, "TEVA reported 2Q12 adj. EPS of $1.28, slightly above our $1.27 est., on rev. of $~5B, vs. our est. of ~$5.1B. We note that TEVA launched 12 products during the quarter, representing $17B in brand value. TEVA purchased ~3.5M shares ($35M aggregate spend) during 2Q12 ($667M aggregate spend on $3B repurchase program in 1H12). We highlight that TEVA also paid down ~$500M in debt and refinanced $3.4B of short-term debt which improved debt-to-EBITDA ratio to 2.2x from 2.6x. We adjust our estimates and look for insight from management into long-term strategic initiatives, pipeline developments, and BD commentary at the 12/11 Analyst Day."
FY12 EPS Estimate raised from $5.38 to $5.40 and FY13 from $5.91 to $6.01.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
